Teva Overview

Teva introduction
2014
1
2
Our Vision
Being the most indispensable
medicines company for the world,
executing on our obligation to
our patients, customers,
shareholders and employees
We have Profound Foundations
111
years in
existence
73
manufacturing
sites
55,000+
SKUs
$20.3B
$5.01
2013 revenues
2013 EPS
45,000
employees
73B
tablets and
capsules per
annum
60
countries
1,000
molecules
Core Strengths
Leading
healthcare
provider
Balanced
business
model
Manufacturing
strengths
Integrated
R&D
Partnering
experience
Entrepreneurial
employees and
culture
Go-to-market
capabilities
A truly global operations network
Financial Growth
2012
2013
Sales $M
20,317
20,314
Operating Income $M
5,715
5,198
Net Income $M
4,671
4,255
* Operating income and net income are non-GAAP results
Our World Changes
Aging population
Increasing competition in generics
Shift in disease patterns
Rising bar for product innovation
Expansion of wealth and health care access
Complicated, expanding global market
Rising health care costs
Generics: a great future
Impact
healthcare system
Global
Pipeline
of high-value products
Sustainable
high-barrier to entry
Branded
generics business
Rapid growth
R&D capabilities
Dramatically enhanced
in selected areas
Research and development
Develop the most competitive
and focused pipeline
to address unmet patient needs
in a highly differentiated way
to drive the growth of Teva
Life and science intimately connected
… that’s uniquely Teva
NTEs - The Future of Teva R&D
High
value
generics
NTEs
Focused
specialty
portfolio
NEW THERAPEUTIC ENTITY
Known molecule that is formulated, delivered, or used in a novel way to
address specific patient needs
Specialty medicines: focus and build leadership
CNS
Protect and expand MS franchise
Build products and pipeline
Respiratory
Invest in capabilities and pipeline
Continue global expansion
New Therapeutic
Entities (NTEs)
Capitalize on unique Teva interface
of Generics and Specialty
Oncology, Women's Selectively invest
Health, Biologics
OTC Business
PGT Consumer Healthcare: JV with P&G leverages value in existing OTC business
World’s leading provider
of medicines
Portfolio of leading brands
Best-in-class
 Consumer understanding
 Brand-building
+
 Advertising scale
World’s leading brandbuilder
Strong product development and
production capabilities
1717
Teva Global Community Statement

Teva is committed to improving global healthcare. We
recognize our responsibility to invest in and support the
communities we serve.

We focus our involvement on the communities in the
countries in which we operate, through a range of activities
that enhance access to medicines and contribute to the
wellbeing of the communities in which we live.

We are proud of our many employees who volunteer in the
community and we support them in a range of ways.
18
19
20